SUNIL SHARMA, MD
Osteopathic Medicine at Circle Of Hope Dr, Salt Lake City, UT
License number
Utah 11224
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2000 Circle Of Hope Dr #3380, Salt Lake City, UT 84112
Phone
(801) 585-0303
(801) 585-0101 (Fax)
(801) 585-0101 (Fax)
Personal information
See more information about SUNIL SHARMA at radaris.comName
Address
Phone
5361 S 2110 E, Salt Lake City, UT 84117
1212 Catherine St, Salt Lake Cty, UT 84116
Organization information
See more information about SUNIL SHARMA at bizstanding.comSunil Sharma MD,MBBS,BS,FACP
2000 Cir Of Hope Dr, Salt Lake City, UT 84112
Industry:
Surgeons, Internist
Phone:
(801) 585-0303 (Phone)
Sunil K. Sharma
Professional information
Division Chief, Medical Oncology At University Of Utah School Of Medicine
Position:
Division Chief, Medical Oncology at University of Utah School of Medicine, Founder at Salarius Pharmaceuticals, Founder at Beta Cat Pharmaceuticals, Director Center for Investigational Therapeutics, Leader: Imaging/Diagnostics/Therapeutics Program at Huntsman Cancer Institute, Professor of Medicine at University of Utah
Location:
Greater Salt Lake City Area
Industry:
Research
Work:
University of Utah School of Medicine
- Greater Salt Lake City Area since Jul 2012
-
Division Chief, Medical Oncology
Salarius Pharmaceuticals
- Greater Salt Lake City Area since Jul 2011
-
Founder
Beta Cat Pharmaceuticals
- Gaithersburg, MD since Dec 2010
-
Founder
Huntsman Cancer Institute
since Jul 2009
-
Director Center for Investigational Therapeutics, Leader: Imaging/Diagnostics/Therapeutics Program
University of Utah
since Jul 2009
-
Professor of Medicine
Nevada Cancer Institute
Dec 2004 - Oct 2008
-
Director, Phase I Programs, Director GI Oncology, Director Clinical Trials Office
Novartis
Jul 2002 - Dec 2004
-
Senior Director, Early Development, Oncology
Memorial Sloan-Kettering Cancer Center
Jul 1998 - Jun 2002
-
Oncologist
Education:
University of Massachusetts at Amherst - Isenberg School of Management 2010 - 2012
The University of Texas Health Science Center at San Antonio 1995 - 1998
Michael Reese Hospital 1990 - 1993
University College of Medical Sciences 1983 - 1988
Sardar Patel Vidyalaya 1981 - 1983
The University of Texas Health Science Center at San Antonio 1995 - 1998
Michael Reese Hospital 1990 - 1993
University College of Medical Sciences 1983 - 1988
Sardar Patel Vidyalaya 1981 - 1983
Skills:
Clinical Research, Translational Research, Epigenetics, Cancer, Oncology, Biotechnology, Clinical Trials, Pharmaceuticals, Therapeutics, Drug Development, Drug Discovery, Life Sciences, Therapists, Pharmaceutical Industry, Molecular Biology, Lifesciences, Clinical Development, Genomics, Cancer Research
Languages:
English, Hindi
Dr. Sunil Sharma - MD (Doctor of Medicine)
Hospitals:
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical Schools
University of Delhi / College of Medical Sciences
University of Delhi / College of Medical Sciences
Substituted N-(3-(Pyrimidin-4-Yl)Phenyl)Acrylamide Analogs As Tyrosine Receptor Kinase Btk Inhibitors
US Patent:
2013005, Mar 7, 2013
Filed:
Apr 1, 2012
Appl. No.:
13/436963
Inventors:
David J. Bearss - Alpine UT, US
Hariprasad Vankayalapati - Draper UT, US
Venkataswamy Sorna - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
Hariprasad Vankayalapati - Draper UT, US
Venkataswamy Sorna - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
International Classification:
C07D 487/04, A61K 31/519, C07D 239/42, C07D 413/12, C07D 403/12, A61P 35/00, A61P 35/02, A61P 29/00, A61P 19/02, A61K 31/506, A61K 31/5377, C07D 239/30
US Classification:
5142342, 544118, 544262, 51425216, 5142621, 544322, 544122, 5142358, 514256, 544334, 51425214, 544295
Abstract:
In one aspect, the invention relates to substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the BTK kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the BTK kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Substituted N-Phenylpyrimidin-2-Amine Analogs As Inhibitors Of The Axl Kinase
US Patent:
2012028, Nov 8, 2012
Filed:
Mar 31, 2012
Appl. No.:
13/436910
Inventors:
David J. Bearss - Alpine UT, US
Hariprasad Vankayalapati - Draper UT, US
Alexis Mollard - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
Hariprasad Vankayalapati - Draper UT, US
Alexis Mollard - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
International Classification:
A61K 31/506, C07D 401/12, A61P 35/00, A61K 31/5377, C07D 403/14, C07D 403/12, C07D 413/14
US Classification:
5142358, 544295, 51425214, 544323, 514275, 544121, 544330, 51425219
Abstract:
In one aspect, the invention relates to substituted N-phenylpyrimidin-2-amine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of Axl kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the Axl kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Substituted 3-(1H-Benzo[D]Imidazol-2-Yl)-1H-Indazole Analogs As Inhibitors Of The Pdk1 Kinase
US Patent:
8569511, Oct 29, 2013
Filed:
Mar 31, 2012
Appl. No.:
13/436905
Inventors:
David J. Bearss - Alpine UT, US
Hariprasad Vankayalapati - Draper UT, US
Venkataswamy Sorna - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
Hariprasad Vankayalapati - Draper UT, US
Venkataswamy Sorna - Salt Lake City UT, US
Steven L. Warner - Sandy UT, US
Sunil Sharma - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/5377, A61K 31/454, A61K 31/4184, C07D 401/14, C07D 403/04, C07D 413/14
US Classification:
5483051, 5142345, 514322, 514394, 544139, 546199
Abstract:
In one aspect, the invention relates to substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the PDK1 kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the PDK1 kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.